Review of vedolizumab for the treatment of ulcerative colitis

Table 1 Principal trial results

Ref.	Sample size (n)	Phase of trial	Treatment arms (n)	Clinical remission (%)	Clinical response (%)
Feagan et al[14], 2005	181	II	Placebo	14	33
			0.5 mg/kg IV	33	66
			2 mg/kg IV	32	53
Parikh et al[15], 2012	47	II	Placebo	33	22-33
			2 mg/kg IV	68-891	> 501
			6 mg/kg IV
			10 mg/kg IV
Feagan et al[16], 2012	374	III
		Induction phase	Placebo	5.4	25.5
			300 mg IV	16.9	47.1
		Maintenance phase	Placebo	15.9	23.8
			300 mg IV 4 weekly	44.8	56.6
			300 mg IV 8 weekly	41.8	52

¹Collective results for all vedolizumab groups combined. IV: Intravenously.